Adams BE, Tunis SL, Edell WS Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS). J Am Med Dir Assoc. 2003 Mar-Apr;4(2):61-6.
Alvarez A, Opazo C, Alarcón R, Garrido J, Inestrosa NC Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol. 1997 Sep 26;272(3):348-61.
Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A Different ß-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging. 2012 Apr;33(4):825.e1-13. doi: 10.1016/j.neurobiolaging.2011.05.003. Epub 2011 Jun 17.
Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.
Gibson Wood W, Eckert GP, Igbavboa U, Müller WE Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim Biophys Acta. 2003 Mar 10;1610(2):281-90. Review.
Haupt M, Kurz A, Jänner M A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 May-Jun;11(3):147-52.
He XX, Yang XH, Ou RY, Ouyang Y, Wang SN, Chen ZW, Wen SJ, Pi RB Synthesis and evaluation of multifunctional ferulic and caffeic acid dimers for Alzheimer's disease. Nat Prod Res. 2017 Mar;31(6):734-737. doi: 10.1080/14786419.2016.1219862. Epub 2016 Aug 17.
Herrmann N Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci. 2001 Feb;28 Suppl 1:S96-107. Review.
Hersch EC, Falzgraf S Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging. 2007;2(4):611-21. Review.
Hixson JE, Vernier DT Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990 Mar;31(3):545-8.
Jacobson, E A., Newmark, H., Baptista, J., & Bruce, W. R. (1983). A preliminary investigation of the metabolism of dietary phenolics in humans [Urinary metabolites of caffeic and ferulic acid]. Nutrition Reports International.
Kanaya, K (2010). Effects of ferulic acid and Angelica archangelica extract (Feruguard) in patients with Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 6(4), S548.
Kanski J, Aksenova M, Stoyanova A, Butterfield DA Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. J Nutr Biochem. 2002 May;13(5):273-281.
Kar N Behavioural and Psychological Symptoms of Dementia. In: Kar N, Jolley D, Misra N, editors. Handbook of Dementia. Hyderabad: Paras Medical Publisher; 2005. pp. 54-74.
Kimura T, Hayashida H, Murata M, Takamatsu J Effect of ferulic acid and Angelica archangelica extract on behavioral and psychological symptoms of dementia in frontotemporal lobar degeneration and dementia with Lewy bodies. Geriatr Gerontol Int. 2011 Jul;11(3):309-14. doi: 10.1111/j.1447-0594.2010.00687.x. Epub 2011 Jan 28.
Kimura, T (2014). A Pilot Study of Tretment with Ferulic Acid and Angelica archangelica Extract for Cognitive Impairment. Journal of New Remedies & Clinics, 63(11), 1848-1855.
Lempereur, I , Rouau, X., & Abecassis, J. (1997). Arabinoxylan and ferulic acid variation in durum wheat (Triticum durum Desf.) grain and distribution in mill streams. J. Cereal Sci, 25, 103-110.
Lin SY, Lewis FM Dementia friendly, dementia capable, and dementia positive: concepts to prepare for the future. Gerontologist. 2015 Apr;55(2):237-44. doi: 10.1093/geront/gnu122. Epub 2015 Feb 15.
Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T Ferulic acid is a nutraceutical ß-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. PLoS One. 2013;8(2):e55774. doi: 10.1371/journal.pone.0055774. Epub 2013 Feb 8.
Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4.
Nielsen RE, Lolk A, M Rodrigo-Domingo, Valentin JB, Andersen K Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer's dementia. Eur Psychiatry. 2017 May;42:14-23. doi: 10.1016/j.eurpsy.2016.11.013. Epub 2016 Dec 12.
Ono K, Hirohata M, Yamada M Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun. 2005 Oct 21;336(2):444-9.
Ou L, Kong LY, Zhang XM, Niwa M Oxidation of ferulic acid by Momordica charantia peroxidase and related anti-inflammation activity changes. Biol Pharm Bull. 2003 Nov;26(11):1511-6.
Ou, S , & Kwok, K. C. (2004). Ferulic acid: pharmaceutical functions, preparation and applications in foods. Journal of the Science of Food and Agriculture, 84(11), 1261-1269.
Porat Y, Abramowitz A, Gazit E Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des. 2006 Jan;67(1):27-37. Review.
Salthouse TA What do adult age differences in the Digit Symbol Substitution Test reflect? J Gerontol. 1992 May;47(3):P121-8.
Sgarbossa A, Giacomazza D, di Carlo M Ferulic Acid: A Hope for Alzheimer's Disease Therapy from Plants. Nutrients. 2015 Jul 15;7(7):5764-82. doi: 10.3390/nu7075246. Review.
Sigurdsson S, Gudbjarnason S Effect of oral imperatorin on memory in mice. Biochem Biophys Res Commun. 2013 Nov 15;441(2):318-20. doi: 10.1016/j.bbrc.2013.10.036. Epub 2013 Oct 16.
Smith T, Gildeh N, Holmes C The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007 May;52(5):329-32.
Sosulski, F , Krygier, K., & Hogge, L. (1982). Free, esterified, and insoluble-bound phenolic acids. 3. Composition of phenolic acids in cereal and potato flours. Journal of Agricultural and Food Chemistry, 30(2), 337-340.
Srinivasan M, Sudheer AR, Menon VP Ferulic Acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr. 2007 Mar;40(2):92-100. doi: 10.3164/jcbn.40.92.
Sul D, Kim HS, Lee D, Joo SS, Hwang KW, Park SY Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci. 2009 Feb 27;84(9-10):257-62. doi: 10.1016/j.lfs.2008.12.001. Epub 2008 Dec 7.
Ware J Jr, Kosinski M, Keller SD A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33.
Wszelaki N, Paradowska K, Jamróz MK, Granica S, Kiss AK Bioactivity-guided fractionation for the butyrylcholinesterase inhibitory activity of furanocoumarins from Angelica archangelica L. roots and fruits. J Agric Food Chem. 2011 Sep 14;59(17):9186-93. doi: 10.1021/jf201971s. Epub 2011 Aug 9.
Wynn ZJ, Cummings JL Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17(1-2):100-8. Epub 2003 Oct 15. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.